NCT02999672 - A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 23, 2016

Primary Completion Date

April 10, 2018

Study Completion Date

April 10, 2018

Conditions

Bladder CancerPancreas CancerCholangiocellular Carcinoma

Interventions

DRUG

Trastuzumab Emtansine

Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.

Trial Locations (16)

20132

Irccs Ospedale San Raffaele;Oncologia Medica, Milan

20141

Irccs Istituto Europeo Di Oncologia (IEO); Cure Mediche, Milan

28034

Hospital Ramon y Cajal; Servicio de Oncologia, Madrid

28041

Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid

29010

Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Málaga

31008

Complejo Hospitalario de Navarra, Pamplona

35128

IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima, Padua

37134

A.O.U.I. VERONA-OSPEDALE POLICLINICO G.B. ROSSI BORGO ROMA;ONCOLOGIA MEDICA-d.U., Verona

47014

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola

1066 CX

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

1081 HV

Amsterdam UMC Location VUMC, Amsterdam

9700 RB

UMCG, NL -groningen

3000 CA

Erasmus MC - Centrum, NL -rotterdam

833 10

Narodny onkologicky ustav, Bratislava

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

08907

Hospital Duran i Reynals; Oncologia, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY